1 completed, 1 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Ovarian function suppression: new trials by email Literature Review of Ovarian function suppression trials Research Report on Ovarian function suppression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer Tucidinostat, Exemestane, Ovarian function suppression - Breast Cancer | Phase 2 | Completed | First Affiliated Hospital, Sun Yat-Sen University | 30 | 2020-07-08 | 2023-10-17 |
Breast Neoplasms (2)
First Affiliated Hospital, Sun Yat-Sen University (1) · Hebei Medical University Fourth Hospital (1)
China (1)
Ying Lin, MD (1)